CoChat

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design. On the basis of sequence analysis and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity. Detailed structure-activity relationship data are shown. Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body weight in diet-induced obese (DIO) mice. Structural analysis by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chemical and physical stability.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b00174

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. Pegapamodutide, C16H27N3O7S, PubChem.https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties(accessed Mar 21, 2017) .

Cited by

See all 111

Metadata

Authors
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., Lorenz, K., Kadereit, D., & Wagner, M.
Affiliations
Sanofi (Germany) (DE)
Corresponding author
  • Evers, Andreas
  • Wagner, Michael
Venue
Journal of Medicinal Chemistry
Published
2017-05-05
Volume
60
Issue
10
Pages
4293-4303
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2608961189
Cited by
101
References
47
Citations by year
2026: 5 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 10 · 2020: 22 · 2019: 18 · 2018: 16 · 2017: 3
FWCI
13.18
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
exendin-4, GLP-1 receptor agonists, glucagon receptor agonist, dual receptor agonist, diabesity, structure-based design, structure-activity relationship, unnatural amino acids, modified amino acids, peptide stability, blood glucose reduction, db/db mice, diet-induced obesity, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Amino Acid Sequence, Animals, Blood Glucose, Body Weight, Female, Glucagon, Hypoglycemic Agents, Mice, Inbred C57BL, Mice, Obese, Obesity, Peptides, Structure-Activity Relationship, Swine, Venoms, Drug Design, Glucagon-Like Peptide 1, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00174
The paper
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., Lorenz, K., Kadereit, D., & Wagner, M. (2017). Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.